HomeCompareNTP vs PFE

NTP vs PFE: Dividend Comparison 2026

NTP yields 227.12% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NTP wins by $39.7K in total portfolio value
10 years
NTP
NTP
● Live price
227.12%
Share price
$4.22
Annual div
$9.57
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.8K
Annual income
$102.29
Full NTP calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — NTP vs PFE

📍 NTP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTPPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTP + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTP pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTP
Annual income on $10K today (after 15% tax)
$19,305.04/yr
After 10yr DRIP, annual income (after tax)
$86.95/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $23,042.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTP + PFE for your $10,000?

NTP: 50%PFE: 50%
100% PFE50/50100% NTP
Portfolio after 10yr
$71.0K
Annual income
$13,656.41/yr
Blended yield
19.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NTP
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTP buys
0
PFE buys
0
No recent congressional trades found for NTP or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTPPFE
Forward yield227.12%6.20%
Annual dividend / share$9.57$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$90.8K$51.1K
Annual income after 10y$102.29$27,210.54
Total dividends collected$43.3K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NTP vs PFE ($10,000, DRIP)

YearNTP PortfolioNTP Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$22,056$11,355.91$9,161$701.38+$12.9KNTP
2$35,304$11,703.97$8,610$859.79+$26.7KNTP
3$46,529$8,754.18$8,366$1,081.25+$38.2KNTP
4$55,178$5,391.46$8,483$1,405.66+$46.7KNTP
5$62,028$2,987.66$9,084$1,907.24+$52.9KNTP
6$67,939$1,569.42$10,418$2,732.78+$57.5KNTP
7$73,498$803.27$13,007$4,193.56+$60.5KNTP
8$79,049$406.07$18,010$7,005.87+$61.0KNTP
9$84,787$204.08$28,216$12,979.89+$56.6KNTP
10$90,824$102.29$51,081$27,210.54+$39.7KNTP

NTP vs PFE: Complete Analysis 2026

NTPStock

Nam Tai Property Inc., through its subsidiaries, owns, develops, and operates technology parks in the People's Republic of China. It focuses on redeveloping three parcels of land in Gushu and Guangming, Shenzhen into technology parks, as well as rents properties. The company was formerly known as Nam Tai Electronics, Inc. and changed its name to Nam Tai Property Inc. in April 2014. Nam Tai Property Inc. was founded in 1975 and is headquartered in Shenzhen, the People's Republic of China.

Full NTP Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NTP vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTP vs SCHDNTP vs JEPINTP vs ONTP vs KONTP vs MAINNTP vs JNJNTP vs MRKNTP vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.